Angus Liu - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Angus Liu's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Angus Liu
Verified
Deputy Editor, Fierce Biotech
Washington
Beats
Covers: News Arts and Culture
non for now
Content
Fierce Pharma Asia—The latest on Trump's tariffs; Leqembi's EU approval; Kyowa Kirin's biologics plant
By Angus Liu Verified| FiercePharma Verified The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. The European Commission has approved Eisai and Biogen's Leqembi in Alzheimer's disease. Kyowa Kirin has finished the build-out of a Japanese biologics plant. And more. 1.
By Angus Liu Verified| FiercePharma Verified GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has become the first to sign off on Blenrep as part of two different combinations for treating multiple myeloma patients who have received at least one prior therapy, GSK said Thursday.
Fierce Pharma Asia—The latest on Trump's tariffs; Leqembi's EU approval; Kyowa Kirin's biologics plant
By Angus Liu Verified| FiercePharma Verified The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. The European Commission has approved Eisai and Biogen's Leqembi in Alzheimer's disease. Kyowa Kirin has finished the build-out of a Japanese biologics plant. And more. 1.
Company Info
Fierce Biotech
Washington, D.C., United States, United States